SCHEMBL2924035

SCHEMBL2924035

CCOC(=O)c1c(N2CCOCC2)ccc(N)c1N

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.47
PIK3CA P42336 1/20 0.47
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 4/20 0.46
GAA P10253 3/20 0.45
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DGAT1 O75907 2/20 0.43
SOAT1 P35610 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932033 0.88 KDM4E (0.46) LGMNL3MBTL1ALDH1A1KDM4EGAA
SCHEMBL2931469 0.83 ALDH1A1 (0.52) L3MBTL1ALDH1A1KDM4EGAALMNA
SCHEMBL27961496 0.80 PKM (0.49) LGMNPIK3CAALDH1A1KDM4EGAA
SCHEMBL15487529 0.77 GAA (0.58) LGMNPIK3CAALDH1A1KDM4EGAA
SCHEMBL14437127 0.76 L3MBTL1 (0.43) LGMNL3MBTL1PIK3CAALDH1A1KDM4E
SCHEMBL4100817 0.74 GAA (0.53) LGMNL3MBTL1PIK3CAALDH1A1KDM4E
SCHEMBL17827898 0.74 LGMN (0.60) LGMNL3MBTL1PIK3CAALDH1A1KDM4E
SCHEMBL19676902 0.74 LMNA (0.60) L3MBTL1PIK3CAALDH1A1KDM4EGAA
SCHEMBL6609202 0.73 GAA (0.59) L3MBTL1PIK3CAALDH1A1KDM4EGAA
SCHEMBL28923550 0.73 LMNA (0.59) PIK3CAALDH1A1KDM4EGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 EP disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 US disclosed
EP-1910314-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306064-A1 Benzimidazole Derivatives PPARG, PPARD, BRD4 LGMN 4268/4885L3MBTL1 4154/4885PIK3CA 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.